EPC-003

N/A

Report date: 2026/01/21 20:00:47

Base Information

Drug NameEPC-003
Drug Alias NameEPC-003
ClassificationCell and gene therapy > Gene therapyCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionT lymphocyte replacementsImmunologic cytotoxicityCD276 antigen modulators +[4] 
TargetsCD276 antigenInterleukin-13 receptor subunit alpha-2
Therapy Area/IndicationsMultiple MyelomaGlioblastoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesElpis BioPharmaceuticals Corp
China Registration ClassN/A

Develop Information

Active CompaniesElpis BioPharmaceuticals CorpSecond Affiliated Hospital School Of Zhejiang University School Of Medicine
Inactive CompaniesN/A
Active IndicationsMultiple MyelomaGlioblastoma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A